English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduThe federally funded COVID-19 Prevention Network was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic. This vital work to expedite Phase 3 clinical trials also resulted in a ‘treasure trove’ of data, thanks to a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.
Tag: CoVPN
CoVPN Trial: Novavax’s Traditional COVID-19 Vaccine Correlates to Strong Antibody Response, Protection Against SARS-CoV-2
A new analysis of the Novavax PREVENT-19 clinical trial concluded that this recombinant protein vaccine produced an antibody response comparable to mRNA vaccines and, if authorized, could help bolster global vaccine supplies. This is the first study to directly support antibody correlates of protection for a recombinant protein COVID-19 vaccine.
CoVPN’s Faith and Diversity Work Engages Key Communities Impacted by COVID-19
The COVID-19 Prevention Network (CoVPN) released today the CoVPN Faith Initiative and Diversity Report, which provides a snapshot of key work to build trust, inform and engage the communities hardest hit by the pandemic in conversations about faith, COVID-19 and CoVPN clinical trials.